Estetrol – a new stage of combined hormonal contraception

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The paper analyzes the modern literature data on estetrol, a native fetal estrogen that has been proposed as an estrogen component in the combined oral contraceptives, where only ethynyl estradiol has been traditionally used. a number of preclinical and clinical trials have provided evidence that estetrol is an estrogen that has unique properties since it does not affect hepatic parameters and hemostasis, has an antiestrogen effect on breast tissue and in high doses demonstrates an antitumor effect in breast and prostate cancers. Due to the above properties, estetrol has become an estrogen that become potentially safe as a component of the combined oral contraceptive containing 15 mg of estetrol and 3 mg of drospirenon in one tablet to be used in the 24/4 regimen, which have been now completed and shown the high efficacy of the contraceptive agent, as well as due to the minimal side effects: a good patient compliance with its usage. All phases of clinical trials of the new combined hormonal contraceptive containing 15 mg of estetrol and 3 mg of drospirenone in one tablet to be used in the 24/4 regimen, which have now been completed and shown the high efficacy of the contraceptive agent, a high safety, as well as due to the minimal side effects: a good patient compliance with its usage. Phase III trials of the new combined hormonal contraceptive, which have now been completed and shown that the new agent esterette is already available for patients and physicians.

Conclusion: The new hormonal combined oral contraceptive with a fetal estrogen, estetrol in combination with drispirenone ensures effective contraception, predictable presentations of hemorrhage, and a favorable safety profile.

Full Text

Restricted Access

About the authors

Inna A. Apolikhina

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia; I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia

Author for correspondence.
Email: i_apolikhina@oparina4.ru
ORCID iD: 0000-0002-4581-6295

Dr. Med Sci., Professor, Head of the Department of Aesthetic Gynecology and Rehabilitation, V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia; Professor of the Department of Obstetrics, Gynecology, Perinatology, and Reproductology, Institute of Professional Education, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia; Member of the Board of the Russian Society of Obstetricians and Gynecologists; President of the Association of Aesthetic Gynecology Specialists (AAGS)

Russian Federation, Moscow; Moscow

Vera N. Prilepskaya

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: vprilepskaya@mail.ru
ORCID iD: 0000-0003-3993-7629

Dr. Med. Sci., Professor, Honored Scientist of the Russian Federation, Head of the Scientific Polyclinic Department

Russian Federation, Moscow

Elena A. Gorbunova

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: el_gorbunova@oparina4.ru
ORCID iD: 0000-0002-4723-4299

Obstetrician-Gynecologist, Researcher, Department of Aesthetic Gynecology and Rehabilitation

Russian Federation, Moscow

Elena A. Mezhevitinova

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: mejevitinova@mail.ru
ORCID iD: 0000-0003-2977-9065

Ph.D, Leading Researcher at the Scientific and Polyclinic Department

Russian Federation, Moscow

Anastasia E. Bychkova

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: a_bychkova@oparina4.ru
ORCID iD: 0000-0003-4855-8188

Obstetrician-Gynecologist at the Department of Aesthetic Gynecology and Rehabilitation

Russian Federation, Moscow

References

  1. Прилепская В.Н., Межевитинова Е.А., Назарова Н.М., Якушевская О.В., Аганезова Н.В., Чернуха Г.Е., Кепша М.А. Национальные медицинские критерии приемлемости методов контрацепции (2022): вклад в охрану репродуктивного здоровья женщин. Акушерство и гинекология: новости, мнения, обучение. 2022; 10(4): 53-60. [Prilepskaya V.N., Mezhevitinova E.A., Nazarova N.M., Yakushevskaya O.V., Aganesova N.V., Chernukha G.E., Kepsha M.A. New national medical acceptance criteria for methods of contraception (2022): contribution to women’s reproductive health. Obstetrics and Gynecology: News, Opinions, Training. 2022; 10(4): 53-60. (in Russian)]. https://dx.doi.org/10.33029/2303-9698-2022-10-4-53-60
  2. United Nations, Department of Economic and Social Affairs, Population Division. Contraceptive use by method 2019: data booklet (ST/ESA/SER.A/435). 2019.
  3. Sturtevant R. Long-term experience with Enovid among clinic patients: results after 2 1/2 to 6 years of individual patient use. J. Reprod. Med. 1970; 5(2): 90-5.
  4. Dragoman M.V. The combined oral contraceptive pill -- recent developments, risks and benefits. Best Pract. Res. Clin. Obstet. Gynaecol. 2014; 28(6): 825-34. https://dx.doi.org/10.1016/j.bpobgyn.2014.06.003
  5. Oelkers W.H.K. Drospirenone in combination with estrogens: for contraception and hormone replacement therapy. Climacteric. 2005; 8(Suppl. 3): 19-27. https://dx.doi.org/10.1080/13697130500330341
  6. Valera M.C., Fontaine C., Dupuis M., Noirrit-Esclassan E., Vinel A., Guillaume M. et al. Towards optimization of estrogen receptor modulation in medicine. Pharmacol. Ther. 2018; 189: 123-9. https://dx.doi.org/10.1016/ j.pharmthera.2018.05.002
  7. Arnal J.-F., Lenfant F., Metivier R., Flouriot G., Henrion D., Adlanmerini M. et al. Membrane and nuclear estrogen receptor alpha actions: from tissue specificity to medical implications. Physiol. Rev. 2017; 97(3): 1045-87. https://dx.doi.org/10.1152/physrev.00024.2016
  8. Deroo B.J., Korach K.S. Estrogen receptors and human disease. J. Clin. Invest. 2006; 116(3): 242-6. https://dx.doi.org/10.1172/JCI27987
  9. Сметник А.А., Родионов В.В., Кометова В.В., Бурменская О.В., Дардык М.В., Сенча А.Н., Ермакова Е.И., Ашрафян Л.А. Молочная железа и половые гормоны. Акушерство и гинекология. 2021; 12: 58-66. [Smetnik A.A., Rodionov V.V., Kometova V.V., Burmenskaya O.V., Dardyk M.V., Sencha A.N., Ermakova E.I., Ashrafyan L.A. The breast and sex hormones. Obstetrics and Gynecology. 2021; (12): 58-66. (in Russian)]. https://dx.doi.org/10.18565/aig.2021.12.58-66
  10. Tulchinsky D., Frigoletto F.D. Jr, Ryan K.J., Fishman J. Plasma estetrol as an index of fetal well-being. J. Clin. Endocrinol. Metab. 1975; 40(4): 560-7. https://dx.doi.org/10.1210/jcem-40-4-560
  11. Bastianelli C., Farris M., Rosato E., Brosens I., Benagiano G. Pharmacodynamics of combined estrogen-progestin oral contraceptives: 1. Effects on metabolism. Expert Rev. Clin. Pharmacol. 2017; 10(3): 315-26. https://dx.doi.org/ 10.1080/17512433.2017.1271708
  12. Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric. 2005; 8(Suppl. 1): 3-63. https://dx.doi.org/10.1080/13697130500148875
  13. Hagen A., Barr M. Metabolism of 17β-oestradiol-4-14C in early infancy. Acta Endocrinol. (Copenh.). 1965; 49: 207-20.
  14. Fruzzetti F., Fidecicchi T., Montt Guevara M.M., Simoncini T. Estetrol: a new choice for contraception. J. Clin. Med. 2021; 10(23): 5625. https://dx.doi.org/10.3390/jcm10235625.
  15. Holinka C.F., Diczfalusy E., Coelingh Bennink H.J. Estetrol: a unique steroid in human pregnancy. J. Steroid Biochem. Mol. Biol. 2008; 110(1-2): 138-43. https://dx.doi.org/10.1016/j.jsbmb.2008.03.027
  16. Warmerdam E.G.J.C., Visser M., Coelingh Bennink H.J.T., Groen M. A new route of synthesis of estetrol. Climacteric. 2008; 11(Suppl. 1): 59-63. https://dx.doi.org/10.1080/13697130802054078
  17. Visser M., Holinka C.F., Coelingh Bennink H.J.T. First human exposure to exogenous single-dose oral estetrol in early postmenopausal women. Climacteric. 2008; 11(Suppl. 1): 31-40. https://dx.doi.org/10.1080/ 13697130802056511
  18. Gérard C., Mestdagt M., Tskitishvili E., Communal L., Gompel A., Silva E. et al. Combined estrogenic and anti-estrogenic properties of estetrol on breast cancer may provide a safe therapeutic window for the treatment of menopausal symptoms. Oncotarget. 2015; 6(19): 17621-36. https://dx.doi.org/10.18632/oncotarget.4184
  19. Schmidt M., Lenhard H., Hoenig A., Zimmerman Y., Krijgh J., Jansen M., Coelingh Benninket H.J.T. Tumor suppression, dose-limiting toxicity and wellbeing with the fetal estrogen estetrol in patients with advanced breast cancer. J. Cancer Res. Clin. Oncol. 2021; 147(6): 1833-42. https://dx.doi.org/10.1007/s00432-020-03472-8
  20. Coelingh Bennink H.J.T., Van Moorselaar J.A., Crawford E.D., Roos E.P.M., Somford D.M., Roeleveld T.A. et al. Estetrol cotreatment of androgen deprivation therapy in infiltrating or metastatic, castration-sensitive prostate cancer: a randomized, double-blind, phase II trial (PCombi). Eur. Urol. Open Sci. 2021; 28: 52-61. https://dx.doi.org/10.1016/ j.euros.2021.04.005
  21. Estetra S.P.R.L. A randomized double-blind placebo controlled phase 3 trial to evaluate the efficacy and safety of estetrol for the treatment of moderate to severe vasomotor symptoms in postmenopausal women (E4Comfort Study I, II). EUDRACT 2019-001289-14. Clinicaltrials.gov NCT04209543, Clinicaltrials.Gov NCT04090957
  22. Gemzell-Danielsson K., Apter D., Zatik J., Weyers S., Piltonen T., Suturina L. et al. Estetrol-drospirenone combination oral contraceptive: a clinical study of contraceptive eficacy, bleeding pattern and safety in Europe and Russia. BJOG. 2022; 129(1): 63-71. https://dx.doi.org/10.1111/1471-0528.16840
  23. Creinin M.D., Westhoff C.L., Bouchard C., Chen M.J., Jensen J.T., Kaunitz A.M. et al. Estetrol-drospirenone combination oral contraceptive: North American phase 3 efficacy and safety results. Contraception. 2021; 104(3): 222-8. https://dx.doi.org/10.1016/j.contraception.2021.05.002
  24. Morimont L., Dogne J.M., Douxfils J. Letter to the editors-in-chief in response to the article of Abou-Ismail, et al. Entitled “estrogen and thrombosis: a bench to bedside review. Thromb. Res. 2020; 193: 221-3. https://dx.doi.org/10.1016/ j.thromres.2020.08.006
  25. Morimont L., Jost M., Gaspard U., Foidart J.M., Dogné J.M., Douxfils J. Low thrombin generation in users of a contraceptive containing estetrol and drospirenone. J. Clin. Endocrinol. Metab. 2022; 108(1): 135-43. https://dx.doi.org/10.1210/clinem/dgac511
  26. Mawet M., Maillard C., Klipping C., Zimmerman Y., Foidart J.M., Coelingh Bennink H.J.T. Unique effects on hepatic function, lipid metabolism, bone and growth endocrine parameters of estetrol in combined oral contraceptives. Eur. J. Contracept. Reprod. Health Care. 2015; 20(6): 463-75. https://dx.doi.org/ 10.3109/13625187.2015.1068934
  27. Gallez A., Blacher S., Maquoi E., Konradowski E., Joiret M., Primac I. et al. Estetrol combined to progestogen for menopause or contraception indication is neutral on breast cancer. Cancers (Basel). 2021; 13(10): 2486. https://dx.doi.org/10.3390/cancers13102486
  28. Lee A., Syed Y.Y. Estetrol/drospirenone: a review in oral contraception. Drugs. 2022; 82(10): 1117-25. https://dx.doi.org/10.1007/s40265-022-01738-8. Erratum in: Drugs. 2022; 82(12): 1341.
  29. Сутурина Л.В., Дикке Г.Б. Опыт применения у молодых женщин низкодозированной левоноргестрел-содержащей внутриматочной системы LCS16 и комбинированного орального контрацептива, содержащего 30 мкг этинилэстрадиола и 3 мг дроспиренона. Акушерство и гинекология. 2021; 11: 230-6. [Suturina L.V., Dikke G.B. Experience in the use of low-dosed levonorgestrel-containing intrauterine system LCS16 and combined oral contraceptive containing 30 mcg ethinyl estradiol and 3 mg drospirenone in young women. Obstetrics and Gynecology. 2021; (11): 230-6. (in Russian)]. https://dx.doi.org/10.18565/aig.2021.11.230-236

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Figure

Download (83KB)
Indexing metadata

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies